Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Biological: Nivolumab
- Registration Number
- NCT03090737
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 129
- Non small cell lung cancer (Squamous or non-squamous)
- At least one prior anti-cancer therapy that did not work
- ECOG Performance Scale 0-1
- Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
- Active, known or suspected autoimmune disease or infection
- Prior immuno-oncology therapy
- Corticosteroids within 2 weeks of study drug administration
Other protocol defined inclusion/exclusion criteria could apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Nivolumab Nivolumab Specified Dose on Specified Days
- Primary Outcome Measures
Name Time Method The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) From the first dose of study treatment to up to 30 days of the last dose of study treatment (up to 24 months) The number of participants who experienced at least 1 select AE of Grade 3-5, judged to be related to study drug per investigator with onset on or after first dose of study treatment and within 30 days of last dose of study treatment, divided by number of treated participants. AE grade is defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 criteria. The select AEs consist of pulmonary events, gastrointestinal events, hepatic events, renal events, skin events, endocrine events categories, thyroid disorders, diabetes, pituitary, adrenal disorder subcategories. Grade 3 is defined as severe or medically significant but not immediately life-threatening. Grade 4 is defined as life-threatening consequences and urgent intervention indicated. Grade 5 is defined as death related to AE.
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) From first dose to the date of the first documented tumor progression (up to approximately 5 months) Progression free survival (PFS) is defined as the time between the date of randomization and the date of the first documented tumor progression accounting for subsequent therapy, based on BICR (blinded independent central review) assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first. Participants will be censored at the last evaluable tumor assessment on or prior to the date of subsequent therapy. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
Objective Response Rate (ORR) From the date of first dose to the date of the initial objectively documented tumor progression or the date of subsequent therapy, whichever occurs first (up to approximately 25 months). Objective Response Rate (ORR) defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by investigator per RECIST 1.1. Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions. Radiographic tumor assessments will be conducted at Week 8 (+/- 7 days) and every 8 weeks (+/- 7 days) until up to 2 years or until disease progression (or until discontinuation of study therapy in patients receiving nivolumab beyond progression), lost to follow-up, or withdrawal of study consent.
Overall Survival (OS) From first dosing date and the date of death due to any cause (up to approximately 4 years and 9 months) Overall Survival (OS) is defined as the time between the first dosing date and the date of death due to any cause. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive.
Duration of Response (DOR) From the date of first confirmed response up to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first (up to approximately 48 months). Duration of Response (DOR) is defined as the time between the date of first confirmed response up to the date of the first documented tumor progression (per RECIST 1.1) as determined by complete response (CR) or partial response (PR), or death due to any cause, whichever occurs first. Participants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including palliative local therapy) without a prior reported progression will be censored at the last evaluable tumor assessment prior to or on the date of initiation of the subsequent anti-cancer therapy (including palliative local therapy). Complete response is defined as the disappearance of all target lesions and the reduction of any pathological lymph nodes to \<10 mm. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions.
Trial Locations
- Locations (17)
Local Institution - 0012
🇿🇦George, Western CAPE, South Africa
Local Institution - 0018
🇯🇵Koto-ku, Tokyo, Japan
Local Institution - 0023
🇯🇵Osaka-shi, Osaka, Japan
Local Institution - 0016
🇯🇵Tokyo, Japan
St Vincent Frontier Cancer Center
🇺🇸Billings, Montana, United States
Guthrie Medical Group Sayre
🇺🇸Sayre, Pennsylvania, United States
Broome Oncology
🇺🇸Johnson City, New York, United States
Local Institution - 0011
🇿🇦Port Elizabeth, Eastern Cape, South Africa
Local Institution - 0015
🇨🇦Kingston, Ontario, Canada
Local Institution - 0003
🇷🇴Craiova, Romania
Local Institution - 0001
🇨🇦Toronto, Ontario, Canada
Local Institution - 0006
🇷🇴Sector 2, Romania
Local Institution - 0017
🇯🇵Nagoya, Aichi, Japan
Alabama Oncology
🇺🇸Birmingham, Alabama, United States
Los Angeles Hematology Oncology Medical Group
🇺🇸Los Angeles, California, United States
Local Institution - 0013
🇿🇦Parktown, Johannesburg, Gauteng, South Africa
Local Institution - 0014
🇨🇦Oshawa, Ontario, Canada